Serum Sclerostin in Hepatitis C Virus Infected Patients
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Sclerostin inhibits osteoblast functions, differentiations, and survival rates. As an endogenous inhibitor of the Wnt/β-catenin pathway, the sclerostin should be re-lated to decreased bone masses, although several studies indicate opposite results. Inaddition, it may be related to insulin resistances and carbohydrate metabolisms, a rela-tion shared with other markers of bone metabolisms, such as osteocalcin. Hepatitis C vi-rus (HCV) infected patients may present osteoporosis, and frequently show liver steato-sis, which is a consequence of insulin resistance. The behaviour of sclerostin in these pa-tients is yet unknown. The aim of this work is to analyse the relationships between se-rum sclerostin and osteocalcin levels and bone mineral density (BMD), liver functions,the intensity of liver steatosis and biochemical markers of bone homeostasis and insulinresistance in HCV-infected patients. Methods: Forty HCV patients with 20 years of ageand gender-matching controls were included in this study and underwent bone densi-tometry. Serum sclerostin, osteocalcin, collagen telopeptide, adiponectin, leptin, insulin,resistin, tumor necrosis factor (TNF)-α, and interleukin (IL)-6 were determined. Liver fatwas histomorphometrically assessed. Results: Sclerostin levels were slightly higher inpatients than in controls, and were directly related to BMD at different parts of the skele-ton, also to the serum telopeptide, and to the liver steatosis and TNF-α. On the contrary,osteocalcin showed a significant direct relationship with serum adiponectin, and an in-verse one with IL-6. Conclusions: Serum sclerostin levels were within the normal rangein HCV patients, and correlated directly with BMD and serum telopeptide. In addition,the relationships of sclerostin and osteocalcin with variables associated with insulin re-sistance suggested the role of bones for intermediary metabolisms.
Abstract
Background: Sclerostin inhibits osteoblast functions, differentiations, and survival rates. As an endogenous inhibitor of the Wnt/β-catenin pathway, the sclerostin should be re-lated to decreased bone masses, although several studies indicate opposite results. Inaddition, it may be related to insulin resistances and carbohydrate metabolisms, a rela-tion shared with other markers of bone metabolisms, such as osteocalcin. Hepatitis C vi-rus (HCV) infected patients may present osteoporosis, and frequently show liver steato-sis, which is a consequence of insulin resistance. The behaviour of sclerostin in these pa-tients is yet unknown. The aim of this work is to analyse the relationships between se-rum sclerostin and osteocalcin levels and bone mineral density (BMD), liver functions,the intensity of liver steatosis and biochemical markers of bone homeostasis and insulinresistance in HCV-infected patients. Methods: Forty HCV patients with 20 years of ageand gender-matching controls were included in this study and underwent bone densi-tometry. Serum sclerostin, osteocalcin, collagen telopeptide, adiponectin, leptin, insulin,resistin, tumor necrosis factor (TNF)-α, and interleukin (IL)-6 were determined. Liver fatwas histomorphometrically assessed. Results: Sclerostin levels were slightly higher inpatients than in controls, and were directly related to BMD at different parts of the skele-ton, also to the serum telopeptide, and to the liver steatosis and TNF-α. On the contrary,osteocalcin showed a significant direct relationship with serum adiponectin, and an in-verse one with IL-6. Conclusions: Serum sclerostin levels were within the normal rangein HCV patients, and correlated directly with BMD and serum telopeptide. In addition,the relationships of sclerostin and osteocalcin with variables associated with insulin re-sistance suggested the role of bones for intermediary metabolisms.
참고문헌 (35)
- van Bezooijen RL., "Bone morphogenetic proteins and their antagonists: the sclerostin paradigm", J Endocrinol Invest., 28(Suppl), pp.15~17 (2005)
- Williams BO., "Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone", J Bone Miner Res., 24, pp.171~181 (2009)
- Li X., "Sclerostin binds to LRP5", 6 and antagonizes canonical Wnt signaling, 2005, pp.280, 19883~19887
- Gaudio A., "Sclerostin levels associated with inhibition of the Wnt", beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus, 2012, pp.97, 3744~3750
- Ardawi MS., "Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study", J Clin Endocrinol Metab., 97, pp.3691~3699 (2012)
- van Bezooijen RL., "Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist", J Exp Med., 199, pp.805~814 (2004)
- Poole KE., "Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation", FASEB J., 19, pp.1842~1844 (2005)
- Sheng Z., "Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women", Clin Endocrinol (Oxf)., 76, pp.797~801 (2012)
- Faje AT., "Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls", Bone., 51, pp.474~479 (2012)
- García-Martín A., "Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus", J Clin Endocrinol Metab., 97, pp.234~241 (2012)
- González-Reimers E., "Serum sclerostin in alcoholics: a pilot study", Alcohol Alcohol., 48, pp.278~282 (2013)
- Cejka D., "Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients", Nephrol Dial Transplant., 27, pp.226~230 (2012)
- Polyzos SA., "Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide", Osteoporos Int., 23, pp.1171~1176 (2012)
- Yavropoulou MP., "Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover", Bone., 51, pp.153~157 (2012)
- Morales-Santana S., "Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels", Diabetes Care., 36, pp.1667~1674 (2013)
- Gennari L., "Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes", J Clin Endocrinol Metab., 97, pp.1737~1744 (2012)
- Starup-Linde J., "Diabetes, biochemical markers of bone turnover, diabetes control, and bone", Front Endocrinol (Lausanne)., 4, pp.21~ (2013)
- Woreta TA., "Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus", Gastroenterology., 140, pp.809~817 (2011)
- James OF., "Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance", J Hepatol., 29, pp.495~501 (1998)
- Motyl KJ., "Bone and glucose metabolism: a two-way street", Arch Biochem Biophys., 503, pp.2~10 (2010)
- Gallego-Rojo FJ., "Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis", Hepatology., 28, pp.695~699 (1998)
- Corazza GR., "Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis", Dig Dis Sci., 45, pp.1392~1399 (2000)
- Carey EJ., "Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem", Liver Transpl., 9, pp.1166~1173 (2003)
- Schiefke I., "Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection", World J Gastroenterol., 11, pp.1843~1847 (2005)
- Hofmann WP., "Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy", J Viral Hepat., 15, pp.790~796 (2008)
- Nanda KS., "Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women", Clin Gastroenterol Hepatol., 7, pp.894~899 (2009)
- Pelazas-González R., "Bone alterations in hepatitis C virus infected patients", Eur J Intern Med., 24, pp.92~96 (2013)
- Manganelli P., "OPG", RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?, 2005, pp.24, 296~300
- Fiore CE., "Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG", RANKL system, 2005, pp.16, 2180~2184
- Shaker JL., "Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman", J Clin Endocrinol Metab., 83, pp.93~98 (1998)
- Gaudio A., "Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss", J Clin Endocrinol Metab., 95, pp.2248~2253 (2010)
- Wieczorek-Baranowska A., "Osteocalcin and glucose metabolism in postmenopausal women subjected to aerobic training program for 8 weeks", Metabolism., 61, pp.542~545 (2012)
- Confavreux CB., "Higher serum osteocalcin is associated with lower abdominal aortic calcification progression and longer 10-year survival in elderly men of the MINOS cohort", J Clin Endocrinol Metab., 98, pp.1084~1092 (2013)
- Arita Y., "Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity", Biochem Biophys Res Commun., 257, pp.79~83 (1999)
- Ogawa-Furuya N., "Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus", Osteoporos Int., 24, pp.2223~2230 (2013)